SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Stock
Equities
1349
CNE1000000W4
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.08 HKD | -0.48% |
|
-2.35% | -18.43% |
| Sales 2022 | 1.03B 142M 1.12B | Sales 2023 | 851M 118M 921M | Capitalization | 7.32B 1.01B 7.92B |
|---|---|---|---|---|---|
| Net income 2022 | 138M 19.07M 149M | Net income 2023 | 109M 15.06M 118M | EV / Sales 2022 | 5.52 x |
| Net cash position 2022 | 1.16B 161M 1.26B | Net cash position 2023 | 1.18B 163M 1.28B | EV / Sales 2023 | 7.22 x |
| P/E ratio 2022 |
23.6
x | P/E ratio 2023 |
22.1
x | Employees | 948 |
| Yield 2022 |
2.28% | Yield 2023 |
3.02% | Free-Float | 45.47% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.48% | ||
| 1 week | -2.35% | ||
| Current month | -3.26% | ||
| 1 month | -8.77% | ||
| 3 months | -10.73% | ||
| 6 months | -18.75% | ||
| Current year | -18.43% |
1 week
2.03
2.13
1 month
2.032.29
Current year
2.032.59
1 year
2.033.31
3 years
2.035.73
5 years
2.039.26
10 years
2.0312.64
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Li
FOU | Founder | 55 | 96-11-10 |
Da Jun Zhao
FOU | Founder | 54 | 96-11-10 |
Yan Xue
DFI | Director of Finance/CFO | 43 | 10-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Yang Yu
BRD | Director/Board Member | 68 | 13-05-29 |
Bo Shen
BRD | Director/Board Member | 51 | 12-06-28 |
Xiao Long Liu
BRD | Director/Board Member | 67 | 16-05-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 2.08 | -0.48% | 231,000 |
| 24-04-17 | 2.09 | +1.95% | 370,000 |
| 24-04-16 | 2.05 | -1.44% | 829,000 |
| 24-04-15 | 2.08 | -1.42% | 885,000 |
| 24-04-12 | 2.11 | -0.94% | 556,000 |
Delayed Quote Hong Kong S.E., April 18, 2024 at 04:08 am EDT
More quotes
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.43% | 789M | |
| +11.18% | 9.08B | |
| -15.94% | 4.57B | |
| +18.47% | 3.9B | |
| +1.89% | 3.69B | |
| +28.61% | 2.62B | |
| -24.63% | 2.34B | |
| -29.37% | 2.14B | |
| +2.55% | 1.84B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- 1349 Stock
